Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.
-
Figures corrected NBB
Corrected annual account filed for 2022.
Financials
Financial year 2025
SASMAR PHARMACEUTICALS from Overijse, company number BE0507657022, closed financial year 2025 with a result of € 133,640 after tax. For that financial year SASMAR PHARMACEUTICALS recorded revenue of € 1.8 million and equity of € 379,779. Compared with financial year 2024, the result moved from € -97,001 to € 133,640. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 7, 2026.
€ 379,779
▲ 54% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 133,640
▲ still € 97,001 loss in 2024
Profit after tax over the fiscal year.
€ 2,917
▼ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 361,179.
People and assets in 2025
0.7
▼ 3.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 158,541
▼ 54% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,369
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2,235
▼ 34% vs 2024
Loans from banks and other lenders, long and short.
€ 2 million
▼ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,347
▼ 77% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | € 2,417,037 | € 1,965,734 | € 1,777,061 | ▼ 10% |
| Gross margin | € 820,919 | € 471,594 | € 366,473 | € 299,086 | ▼ 18% |
| Profit after taxes | € -234,325 | € 61,513 | € -97,001 | € 133,640 | ▲ € 230,641 |
| Equity | € 281,628 | € 343,141 | € 246,140 | € 379,779 | ▲ 54% |
| Total debts | € 1,360,648 | € 3,076,435 | € 2,949,624 | € 2,694,136 | ▼ 9% |
| Cash | € 14,213 | € 18,478 | € 10,947 | € 2,917 | ▼ 73% |
| Land & buildings | - | € 7,384 | - | - | |
| Retained profit | € 263,028 | € 324,541 | € 227,540 | € 361,179 | ▲ 59% |
| Bank debt | € 610,237 | € 0 | € 3,399 | € 2,235 | ▼ 34% |
| Balance sheet total | € 1,642,276 | € 3,419,576 | € 3,195,764 | € 3,073,916 | ▼ 4% |
| Employees (FTE) | - | - | 4.4 | 0.7 | ▼ 3.7 |
By revenue, SASMAR PHARMACEUTICALS ranks 85th of 90 companies with main activity “Groothandel in farmaceutische en medische artikelen” in Flemish Brabant that publish figures (fiscal year 2025).
Key figures of SASMAR PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about SASMAR PHARMACEUTICALS the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to SASMAR PHARMACEUTICALS?
What happened at SASMAR PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 133,640. filed late Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Overijse. KBO
In short
From € 234,325 loss in 2022 to € 133,640 profit in 2025.
Best year ever: 2025, with € 133,640 profit.
On average € 83,300 of value added per employee in 2024.
Establishments
Establishment units
Physical locations of this company
Sint-Hubertusdreef 26
3090 Overijse
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Flemish Brabant
Same main activity (Groothandel in farmaceutische en medische artikelen), 255 active companies in Flemish Brabant, largest first.
€ 3.6 billion revenue · 2025 · Machelen (Brab.)
Viatris International Supply Point
€ 2.7 billion revenue · 2025 · Hoeilaart
€ 1.2 billion revenue · 2025 · Hoegaarden
€ 799.2 million revenue · 2026 · Leuven
€ 454.7 million revenue · 2025 · Dilbeek
€ 378.6 million revenue · 2025 · Machelen (Brab.)
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- MANCINI HOLDINGS PTY LIMITED(oprichter) 100%
- MANCINI John-Michael(oprichter) 0%
Details
- Company number
- 0507.657.022
- VAT number
- BE 0507.657.022
- Registered office
- Sint-Hubertusdreef 26, 3090 Overijse
- Names & denominations
- SASMAR PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 December 2014
- Peppol
- Active · Active since 8 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Vervaardiging van farmaceutische grondstoffen